Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Assa'ad, S. Gupta, M. Collins, M. Thomson, A. Heath, Deborah Smith, T. Perschy, C. Jurgensen, H. Ortega, S. Aceves (2011)
An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.Gastroenterology, 141 5
J. Oldhoff, U. Darsow, T. Werfel, I. Bihari, K. Katzer, J. Laifaoui, S. Plötz, A. Kapp, E. Knol, C. Bruijnzeel‐Koomen, J. Ring, M. Bruin‐Weller (2006)
No Effect of Anti-Interleukin-5 Therapy (Mepolizumab) on the Atopy Patch Test in Atopic Dermatitis PatientsInternational Archives of Allergy and Immunology, 141
Parameswaran Nair, M. Pizzichini, M. Kjarsgaard, M. Inman, A. Efthimiadis, E. Pizzichini, F. Hargreave, P. O'Byrne (2009)
Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.The New England journal of medicine, 360 10
Sophia Kim, G. Marigowda, Eyal Oren, E. Israel, M. Wechsler (2010)
Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome.The Journal of allergy and clinical immunology, 125 6
G. Furuta, C. Liacouras, M. Collins, S. Gupta, C. Justinich, P. Putnam, P. Bonis, E. Hassall, A. Straumann, M. Rothenberg (2007)
Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment.Gastroenterology, 133 4
A. Straumann, S. Conus, P. Grzonka, H. Kita, G. Kephart, C. Bussmann, C. Beglinger, Deborah Smith, J. Patel, Margaret Byrne, H. Simon (2009)
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trialGut, 59
H. Simon, S. Plötz, R. Dummer, K. Blaser (1999)
Correction: Abnormal Clones of T Cells Producing Interleukin-5 in Idiopathic Eosinophilia.The New England journal of medicine, 341 22
P. Haldar, C. Brightling, B. Hargadon, S. Gupta, W. Monteiro, A. Sousa, R. Marshall, P. Bradding, R. Green, A. Wardlaw, I. Pavord (2009)
Mepolizumab and exacerbations of refractory eosinophilic asthma.The New England journal of medicine, 360 10
S. Willsie (2010)
Mepolizumab and Exacerbations of Refractory Eosinophilic AsthmaYearbook of Pulmonary Disease, 2010
H. Simon, S. Plötz, Reinhard Dummr, K. Blaser (1999)
Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia.The New England journal of medicine, 341 15
Hamid (1991)
Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma.J Clin Invest, 87
P. Flood-Page, C. Swenson, I. Faiferman, J. Matthews, M. Williams, L. Brannick, D. Robinson, S. Wenzel, W. Busse, T. Hansel, N. Barnes (2007)
A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.American journal of respiratory and critical care medicine, 176 11
C. Sanderson (1992)
Interleukin-5, eosinophils, and disease.Blood, 79 12
M. Humbert, C. Corrigan, P. Kimmitt, S. Till, A. Kay, S. Durham, Humbert M, Corrigan Cj, Kay Ab, Durham Rela (1997)
Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma.American journal of respiratory and critical care medicine, 156 3 Pt 1
D. Robinson, Q. Hamid, A. Bentley, S. Ying, A. Kay, S. Durham (1993)
Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma.The Journal of allergy and clinical immunology, 92 2
Another recent publication showing that anti-IL-5 reduces eosinophil numbers in the esophageal tissue of children with eosinophilic esophagitis
M. Stein, M. Collins, J. Villanueva, J. Kushner, P. Putnam, B. Buckmeier, A. Filipovich, A. Assa'ad, M. Rothenberg (2006)
Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.The Journal of allergy and clinical immunology, 118 6
P. Gevaert, D. Lang‐Loidolt, A. Lackner, H. Stammberger, H. Staudinger, T. Zele, G. Holtappels, J. Tavernier, P. Cauwenberge, C. Bachert (2006)
Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps.The Journal of allergy and clinical immunology, 118 5
M. Leckie, A. Brinke, Jamey Khan, Z. Diamant, B. O'connor, Christine Walls, A. Mathur, Hugh Cowley, K. Chung, R. Djukanović, T. Hansel, S. Holgate, P. Sterk, P. Barnes (2000)
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic responseThe Lancet, 356
C. Büttner, A. Lun, T. Splettstoesser, G. Kunkel, H. Renz (2003)
Monoclonal anti-interleukin‐5 treatment suppresses eosinophil but not T‐cell functionsEuropean Respiratory Journal, 21
M. Rothenberg, A. Klion, F. Roufosse, J. Kahn, P. Weller, H. Simon, L. Schwartz, L. Rosenwasser, J. Ring, E. Griffin, A. Haig, P. Frewer, J. Parkin, G. Gleich (2008)
Treatment of patients with the hypereosinophilic syndrome with mepolizumab.The New England journal of medicine, 358 12
N. Yamamoto, H. Sugiura, K. Tanaka, M. Uehara (2003)
Heterogeneity of interleukin 5 genetic background in atopic dermatitis patients: significant difference between those with blood eosinophilia and normal eosinophil levels.Journal of dermatological science, 33 2
Jennifer Garrett, S. Jameson, B. Thomson, M. Collins, L. Wagoner, D. Freese, L. Beck, J. Boyce, A. Filipovich, J. Villanueva, Steven Sutton, A. Assa'ad, M. Rothenberg (2004)
Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.The Journal of allergy and clinical immunology, 113 1
This article is one of the most recent demonstrating efficacy of anti-IL-5 in eosinophilic esophagitis
A. Klion, B. Bochner, G. Gleich, T. Nutman, M. Rothenberg, H. Simon, M. Wechsler, P. Weller (2006)
Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.The Journal of allergy and clinical immunology, 117 6
Florence 2, Michel Goldman2, Elie Cogan1 (2006)
Hypereosinophilic Syndrome: Lymphoproliferative and Myeloproliferative VariantsSemin Respir Crit Care Med, 27
J. Bousquet, P. Chanez, J. Lacoste, G. Barnéon, Nouchine Ghavanian, I. Enander, P. Venge, S. Ahlstedt, J. Simony‐Lafontaine, P. Godard, F. Michel (1990)
Eosinophilic inflammation in asthma.The New England journal of medicine, 323 15
H. Schrezenmeier, Thomé Sd, F. Tewald, B. Fleischer, A. Raghavachar (1993)
Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome.Experimental hematology, 21 2
A. Pardanani, R. Ketterling, chin-Yang Li, M. Patnaik, A. Wolanskyj, M. Elliott, J. Camoriano, J. Butterfield, G. Dewald, A. Tefferi (2006)
FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.Leukemia research, 30 8
This open-label study shows promise of anti-IL-5 in patients with corticsteoridrequiring Churg-Strauss syndrome
A. Mishra, S. Hogan, E. Brandt, M. Rothenberg (2002)
IL-5 Promotes Eosinophil Trafficking to the Esophagus1The Journal of Immunology, 168
M. Koury, J. Newman, J. Murray (2003)
Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib.The American journal of medicine, 115 7
A. Kay, O. Hamid, M. Azzawi, S. Ying, R. Mogbel, A. Wardlaw, C. Corrigan, B. Bradley, S. Durham, J. Collins, P. Jeffery, D. Quint (1991)
Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma.The Journal of clinical investigation, 87 5
E. Clutterbuck, EM Hirst, C. Sanderson (1989)
Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF.Blood, 73 6
J. Oldhoff, U. Darsow, T. Werfel, K. Katzer, A. Wulf, J. Laifaoui, D. Hijnen, S. Plötz, E. Knol, A. Kapp, C. Bruijnzeel‐Koomen, Johannes Ring, M. Bruin-Weller (2005)
Anti‐IL‐5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitisAllergy, 60
A. Klion (2007)
Approach to the therapy of hypereosinophilic syndromes.Immunology and allergy clinics of North America, 27 3
Jonathan Corren Allergy Medical Clinic, Los Angeles, California, USA Purpose of review Interleukin 5 (IL-5) has been shown to play an instrumental role in eosinophilic Correspondence to Jonathan Corren, MD, Allergy Medical Clinic, 10780 Santa Monica Boulevard, inflammation in allergic diseases. The purpose of this review is to explore clinical trials of Suite 280, Los Angeles, CA 90025, USA anti-IL-5 antibody therapy that have been conducted in patients with asthma, Tel: +1 310 312 5050; e-mail: jcorren@ucla.edu hypereosinophilic syndromes, eosinophilic esophagitis, atopic dermatitis, Current Opinion in Allergy and Clinical Churg-Strauss syndrome, and nasal polyposis. Immunology 2011, 11:565–570 Recent findings Recent trials of anti-IL-5 in patients with severe asthma refractory to existing therapies and prominent sputum eosinophilia experienced significant reductions in asthma exacerbations. Studies in patients with hypereosinopihilic syndromes have shown that IL-5 antagonism allows significant reductions in systemic corticosteroid doses while maintaining or improving blood eosinophil counts and symptoms. In children and adults with eosinophilic esophagitis, anti-IL-5 treatment reduced eosinophil numbers in esophageal tissue; it is uncertain whether these findings are predictive of clinical improvement. Clinical studies of individuals with atopic dermatitis do not support efficacy of anti-IL-5 in either reducing allergen patch test intensity or symptoms of chronic
Current Opinion in Allergy and Clinical Immunology – Wolters Kluwer Health
Published: Dec 1, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.